Efficacy of Biological and Steroid Therapies in Adolescent and Adult Patients with Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis with Meta-regression - PubMed
3 hours ago
- #Eosinophilic Esophagitis
- #Network Meta-Analysis
- #Biological Therapies
- Network meta-analysis evaluated biological and steroid therapies for eosinophilic esophagitis (EoE) in patients aged 12+ years, finding all agents except etrasimod achieved histological remission.
- Dupilumab and cendakimab showed moderate-to-high certainty benefits for dysphagia improvement at 12 and 24 weeks, while budesonide oral suspension (BOS) was effective at 12 weeks; budesonide orodispersible tablets (BOT) were highly effective at 48 weeks.
- SUCRA rankings indicated dupilumab ranked highest for dysphagia improvement at 12 and 24 weeks, and BOT 1 mg highest at 48 weeks; for histological remission, BOS 2 mg ranked highest at 12 weeks, benralizumab at 24 weeks, and BOT 1 mg at 48 weeks.
- The review highlighted a dissociation between histologic and symptomatic responses, noting most corticosteroid trials were short-term and lacked direct comparisons with biologics, calling for robust head-to-head trials to optimize treatment strategies.